[an error occurred while processing this directive] | [an error occurred while processing this directive]
Relationship of expression of APAF-1 and COX-2 with pathologic complete response to neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma
Department of Radiation Oncology,First Affiliated Hospital,Sun Yat-Sen University,Guangzhou 510080,China (Peng HH,Zhang T,Dong J,Wang CT,Wen BX);Department of Radiation Oncology (Yu X,You KY,Gao YH), Department of Pathology (Xi SHY,Cai MY,Zhang HZH),Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangzhou 510060,China;Department of Radiation Oncology,Cancer Center of Guangzhou Medical University,Guangzhou 510075,China (Peng HH)
AbstractObjective To investigate the relationship of expression of apoptosis protease-activating factor 1(APAF-1) and cyclooxygenase-2(COX-2) with pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (neo-CRT) for locally advanced rectal adenocarcinoma. Methods Paraffin-embedded tumor tissue sections were collected from 82 patients with locally advanced rectal adenocarcinoma who received neo-CRT and radical surgery from 2005 to 2012. Immunohistochemical assay was used to determine the expression of APAF-1 and COX-2. Postoperative pathological tissue sections were reassessed for evaluation of tumor regression grade (0-4, pCR=4) after radiochemotherapy. The relationship of expression of APAF-1 and COX-2 with pCR was analyzed by chi-square test or Fisher′s exact test. Logistic regression analysis was used to predict the influencing factors for pCR. Results The numbers of patients with grade 0, 1, 2, 3, and 4 tumor regression were 0, 6(7%), 33(40%), 20(24%), and 23(28%), respectively. Patients with high expression of APAF-1 had a significantly higher incidence of pCR than those with low expression of APAF-1(37% vs. 17%, P=0.047), while patients with low expression of COX-2 had a significantly higher incidence of pCR than those with high expression of COX-2(38% vs. 15%, P=0.028). Patients with high expression of APAF-1 and low expression of COX-2 had a significantly higher incidence of pCR than patients with high expression of APAF-1 and COX-2, patients with low expression of APAF-1 and COX-2, and patients with low expression of APAF-1 and high expression of COX-2(56% vs. 14%;56% vs. 17%;56% vs. 15%;P=0.005). The expression of APAF-1 was positively correlated with pCR (P=0.042), while the expression of COX-2 was negatively correlated with pCR (P=0.024). ConclusionsThe expression of APAF-1 and COX-2 is correlated with pCR to neo-CRT for locally advanced rectal adenocarcinoma. The measurement of expression of both APAF-1 and COX-2 holds promise for prediction of pCR.
. Relationship of expression of APAF-1 and COX-2 with pathologic complete response to neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 462-466.
. Relationship of expression of APAF-1 and COX-2 with pathologic complete response to neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 462-466.
[1]Martin ST,Heneghan HM,Winter DC.Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J].Br J Surg,2012,99(7):918-928.DOI:10.1002/bjs.8702. [2]Kundel Y,Brenner R,Purim O,et al. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option?[J].Dis Colon Rectum,2010,53(12):1624-1631.DOI:10.1007/DCR.0b013e3181f5b64 d. [3]Belluco C,De Paoli A,Canzonieri V,et al. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer:implications for local excision surgical strategies[J].Ann Surg Oncol,2011,18(13):3686-3693.DOI:10.1245/s10434-011-1822-0. [4]Wolthuis AM,Penninckx F,Haustermans K,et al. Outcome standards for an organ preservation strategy in stage Ⅱ and Ⅲ rectal adenocarcinoma after neoadjuvant chemoradiation[J].Ann Surg Oncol,2011,18(3):684-690.DOI:10.1245/s10434-010-1324-5. [5]Edden Y,Wexner SD,Berho M.The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma[J].Colorectal Dis,2012,14(5):555-561.DOI:10.1111/j.1463-1318.2011.02697.x. [6]Smith FM,Reynolds JV,Kay EW,et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy[J].Int J Radiat Oncol Biol Phys,2006,64(2):466-472.DOI:10.1016/j.ijrobp.2005.07.961. [7]Dworak O,Keilholz L,Hoffmann A.Pathological features of rectal cancer after preoperative radiochemotherapy[J].Int J Colorectal Dis,1997,12(1):19-23.DOI:10.1007/s003840050072. [8]Negri FV,Campanini N,Camisa R,et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy[J].Br J Cancer,2008,98(1):143-147.DOI:10.1038/sj.bjc.6604131. [9]彭海花,游凯云,王成涛,等.局部晚期直肠癌新辅助放化疗术后病理分期对预后影响[J].中华放射肿瘤学杂志,2013,22(6):439-442.DOI:10.3760/cma.j.issn.1004-4221.2013.06.005. Peng HH,You KY,Wang CT,et al. Prognostic effects of pathological stages in patients with locally advanced rectal cancer after neoadjuvant radiochemotherapy plus radical surgery[J].Chin J Radiat Oncol,2013,22(6):439-442.DOI:10.3760/cma.j.issn.1004-4221.2013.06.005. [10]Maas M,Beets-Tan RGH,Lambregts DMJ,et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer[J].J Clin Oncol,2011,29(35):4633-4640.DOI:10.1200/JCO.2011.37.7176. [11]Adams JM,Cory S.Apoptosomes:engines for caspase activation[J].Curr Opin Cell Biol,2002,14(6):715-720.DOI:10.1016/S0955-0674(02)00381-2. [12]Zlobec I,Vuong T,Compton CC.The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative,high-dose-rate brachytherapy[J].Cancer,2006,106(2):284-286.DOI:10.1002/cncr.21600. [13]Sheehan KM,Steele C,Sheahan K,et al. Association between cyclooxygenase-2-expressing macrophages,ulceration and microvessel density in colorectal cancer[J].Histopathology,2005,46(3):287-295.DOI:10.1111/j.1365-2559.2005.02083.x. [14]Wang D,Dubois RN.Prostaglandins and cancer[J].Gut,2006,55(1):115-122.DOI:10.1136/gut.2004.047100. [15]Kishi K,Petersen S,Petersen C,et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor[J].Cancer Res,2000,60(5):1326-1331. [16]Min BS,Choi YJ,Pyo HR,et al. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer[J].Arch Surg,2008,143(11):1091-1097.DOI:10.1001/archsurg.143.11.1091. [17]Davis TW,O′Neal JM,Pagel MD,et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2,a survival factor for tumor and associated vasculature[J].Cancer Res,2004,64(1):279-285.DOI:10.1158/0008-5472.CAN-03-1168.
2016, Vol. 25 
